ClinicalTrials.gg
RecruitingNCT07944794Updated Nov 18, 2026

Safety and Effectiveness of Different Interface Models for Non-invasive Ventilation Support for Preterm Newborns With a Gestational Age Greater Than or Equal to 28 Weeks.

An interventional study of Infant Flow and Ram Cannula in Respiratory Distress Syndrome in Premature Infants, Non Invasive Ventilation (NIV) and Nasal Injury, sponsored by University of Sao Paulo General Hospital. Recruiting at 1 site in Brazil. Open to participants aged 28 Weeks to 36 Weeks. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Sao Paulo General Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Sep 2025, registered Jun 2026).
  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
28 Weeks to 36 Weeks
Sex
All
01

Study summary

This is a prospective, randomized, stratified clinical trial by gestational age with 5 arms including preterm newborns (PTNBs) with a gestational age (GA) ≥ 28 weeks, in a public hospital in northeastern Brazil.

  • There is no difference in efficacy and safety between the 5 interfaces.
  • To describe the differences in efficacy and safety of the 5 interfaces. After signing the informed consent form, stratification will be performed by gestational age (≥ 28 weeks and \< 32 weeks, and ≥ 32 weeks and \< 37 weeks). After respiratory assessment, if mild to moderate respiratory distress (BSA between 1 and 6) is confirmed. Following randomization for allocation to the groups, eligible newborns who had multiple births will be randomized individually. Those who use mechanical ventilation and who will be extubated will be randomized following the same inclusion criteria.

Patients will be randomly allocated into 5 groups according to the NIV interface:

  • Group 1 (G1) - Infant Flow LP® Interface;
  • Group 2 (G2) - RAM® Cannula;
  • Group 3 (G3) - Dräger Babyflow® Nasal Mask;
  • Group 4 (G4) - Conventional binasal prongs (Ventcare®);
  • Group 5 (G5) - Fanem® Flexible Anatomical Binosal Prongs.

Randomization will be done using sequentially numbered, sealed, opaque envelopes containing the group allocation, separated into two boxes as per the stratification described above. Vital signs and blood pressure will be collected before the use of ventilatory support on a specific data collection form and will continue at 4-hour intervals at the following times (8:00, 12:00, 16:00, 20:00, 0:00, 4:00) until non-invasive ventilation is withdrawn.

Read the detailed description

Research Protocol

Following approval by the Ethics Committee/National Ethics Committee, the multidisciplinary team of the NICU at the Women's Hospital will attend a meeting to present the research and receive the necessary training.

Interventions

Preterm infants (PTNBs) who meet the study inclusion criteria and require ventilatory support, using Vyaire IX5® or Bellavista® mechanical ventilation devices. Humidifiers ( GT5000 , and GT5000 plus - Globaltec Med®), which do not have servo controls , will be used and adjusted according to the temperature and relative humidity control protocol of the gas delivered to the patient as follows:

  • Set the heater initially to power level 5 ;
  • Perform intermittent checks of the supplied gas (every 4 hours);
  • Adjust the heater power to target a temperature between 36.5°C and 37°C;
  • Top up the water level to the indicated mark (every 4 hours); The humidifiers (TR EVOLUTION - TREND Medical), (GT5000S - Globaltec Med®) and (MR850 Fisher \& Paykel®), should be set to non-invasive mode for the 5 groups. The target SpO2 range adopted will be 92% to 96%, following the Unit's routine.

Detailed description of patient randomization according to NIV interface type:

Group 1 - intervention with Infant Flow LP®, will undergo NIV via the interfaces used in the Infant Flow LP® system, according to the study protocol using the AVPM Vyaire IX5® or Bellavista®.

Group 2 - RAM® Cannula, will receive NIV with the RAM® cannula interface, according to the study protocol using the AVPM Vyaire IX5® or Bellavista®.

Group 3 - Dräger Babyflow® nasal mask , will receive NIV via the Dräger Babyflow® interface, according to the study protocol, using the AVPM Vyaire IX5® or Bellavista®.

Group 4 - Conventional binasal prongs will receive NIV with a conventional binasal prong interface ( Ventcare®) according to the study protocol using AVPM Vyaire IX5® or Bellavista®.

Group 5 - Fanem® Flexible Anatomical Binaural Prongs Non-invasive ventilation (NIV) will be administered with a flexible anatomical binasal prong-type interface, as per the study protocol, using the AVPM Vyaire IX5® or Bellavista®.

For adjusting ventilatory parameters :

  1. Adjusting ventilatory parameters in bilevel therapy :

    1. The AVPM will be adjusted for use in neonatal patients, bilevel ventilation mode (two levels of airway pressure);
    2. Inspiratory pressure (IPAP) \< 16 cm H2O ;
    3. PEEP or EPAP between 4 and 6 cmH2O ;
    4. Respiratory rate (RR) is measured according to the rate performed by the preterm newborn at the time, and is reduced every five minutes until it reaches two-thirds of the rate predicted for the newborn's gestational age;
    5. Inspiratory time (Ti) according to the time constant in neonatology (1tc=0.15s);
    6. Flow rate between 6 and 10 L/min;
    7. Initial FiO2 30% and adjust to maintain target SpO2;
  2. To adjust parameters in CPAP :

    1. AVPM will be adjusted for neonatal patients in no nCPAP ventilation mode ;
    2. CPAP between 4 and 6 cmH2O ;
    3. Flow rate between 6 and 10 L/min;
    4. Initial FiO2 30% and adjust to maintain target SpO2;
  3. Infant Flow LP® parameters :

    1. O AVPM using variable flow CPAP ventilation mode® ;
    2. To set the flow rate no AVPM to provide the desired pressure, cover the interface and, check the setting on the AVPM screen. The Infant Flow LP® setting is subject to a direct relationship between flow and pressure; for example, a flow rate of 9 LPM generates a pressure of 5 cmH2O , and the dwell time at high flow will be 0.3 to 0.45 seconds.
    3. Adjust initial parameters with CPAP between 4 and 6 cmH2O , initial FiO2 of 30%, and adjust to maintain target SpO2;
    4. Adjust the servo-controlled humidifier to non-invasive mode to maintain a comfortable temperature and humidity;
    5. With the patient in Fowler's position 30º, after placing the cap, secure it comfortably and without air leaks;
  4. Occlude the nasal prong, mask, or cannula and check if the adjusted parameters have been met.

All patients using NIV will undergo evaluation with inspection of the nasal septum, nasal bridge, nostrils, columella, inner surface of the nostrils using a flashlight, performed on both sides, upper lip and face, points where there is contact with the interface and/or corrugated tube every 4 hours, at the following times (00h, 04h, 08h, 12h, 16h, 20h), until the device is removed.

The airways of preterm infants will be digitally photographed from a distance of 20 cm, using an auxiliary light positioned behind the camera. Facial images of the preterm infants will be taken using digital photogrammetry with an Apple® iPhone® 11 smartphone. This recording will be carried out by the researchers. The photogrammetries will be stored in a folder identified by a patient number (preserving their identity), stored in a Google® drive for this purpose, access to which is restricted to members of this research, guaranteeing the secrecy, confidentiality, and security of the participants' data, as stated in CNS Resolution No. 466 of 2012. The images will be used for analysis; there will be no disclosure of these images.

The newborn will be in a supine position, positioned in front of the examiner so that they can visualize the anterior, superior, and lateral aspects of the face and a regiãothe inside of the nostrils with a small flashlight. The assessment will be performed by the researcher as a preventive measure against pressure ulcers. If there is any doubt in the classification, they should request an evaluation from another member of the team, without disclosing their own impression. Upon identification of a stage 1 (one) lesion with hyperemia, new photographs will be taken, maintaining the same positioning, and a Neo-guard® hydrocolloid barrier dressing will be applied to the nasal region and upper lip, chosen according to the size of the nostril and the interface used, and Hypafix® will be applied to other contact points where Neo-guard® is not suitable.

Neo -guard® should be changed every seven days or if there is moisture or damage to the material.

In cases where upper airway aspiration is indicated, suction will be performed using a No. 6fr suction catheter. Cloreto de Polivinila (Non-toxic, flexible, transparent PVC with a rigorously smooth surface, featuring a rounded open end on the proximal side of the tube and two alternating holes on opposite sides (CPL medical's ®), connected to the negative pressure source, through the Ross Medical® 1000 ml - QinPot closed suction system device with drainage bag, and 0.9% saline solution may be instilled if there is difficulty in removing secretions. As per unit protocol.

Failure criteria will be considered for all groups when there is a need for:

  1. FiO2 above 60%;
  2. > 8 cm H2O ;
  3. PIP > 20 cmH2O or a pressure delta requirement ≥ 12 cmH2O ;
  4. Increase or lack of decrease da frequênciain respiratory rate within two hours of starting NIV (in the absence of fever and pain);
  5. BSA > 6, repeated apneas;
  6. SpO2 /FiO2 ratio ≤180 , if blood gas analysis is required with pH \< 7.22;
  7. Change in behavioral state assessed by Brazelton (state 5 e 6);
  8. Hemodynamic instability;
  9. Severe arrhythmias, bradycardia;
  10. Severe abdominal distension;
  11. Worsening of underlying disease associated with worsening vital signs ;
  12. Stage 3 nasal lesion and/or upper lip lesion ≥ 7;

Research Interruption Criteria

The research protocol may be interrupted if the preterm newborn does not adapt to non-invasive ventilation (NIV) or the interface, and if there is no safe material available for the application of NIV. Intolerance to the use of interfaces is considered to be indicated by: psychomotor agitation, changes in vital signs of 20% more or less than the newborn's baseline, and/or a drop in pulse oxygen saturation (SpO2) below the predicted target for the newborn.

Ethical Aspects

The study will be submitted to the Research Ethics Committee (CEP/CONEP) since the proposing institution does not have its own CEP (Hospital Inácia Pinto dos Santos), as required by Resolution 466/12 of the National Health Council (CNS), guaranteeing the well-being rights of the participants. The legal guardians of each preterm newborn will be invited to participate in the study by reading the Informed Consent Form. No research procedure will disrupt the unit's care routine, in accordance with resolutions currently in force.

There will be no disclosure of any data that could identify the research participants; data collection from medical records will be done using only the patient's registration number at the hospital unit. Research participants will be identified by sequential numbers starting from number 1 on the data collection forms, thus guaranteeing the secrecy, confidentiality, and security of the data in accordance with the General Data Protection Law.

The information collected from the patient's electronic medical record will be compiled into data collection forms and used for research results analysis. This information, necessary for the study, will be transferred to a database in the researcher's institutional email files. This research project aims to evaluate the safety and effectiveness of different interface models for non-invasive ventilation support for preterm newborns with a gestational age of 28 weeks or greater. The data collected between November 1, 2025, and November 31, 2028, will concern the child at birth and during hospitalization, including gestational age, birth weight, type of delivery, sex, length of stay, information on episodes of apnea, bradycardia, antibiotics, laboratory tests, and imaging studies.

The researchers will maintain the confidentiality of the collected data, in accordance with CNS Resolution, and will preserve the anonymity of the individuals whose data were analyzed when publishing the research results. The data will be presented in an aggregated and coded format to reinforce confidentiality and ensure participant anonymity.

Researchers are aware that the integrity of information and the privacy of research participants are the responsibility of the researchers themselves involved in the data collection process; the data collected will not be shared with individuals outside the research team. Research participants are guaranteed the right to seek redress for damages arising from the research.

Statistical analysis

Demographic characteristics and variables and pain scores, behavioral status, and respiratory discomfort will be described according to frequencies and analyzed using Student's t-test (if showing a normal distribution) or the Wilcoxon/Mann-Whitney test. Frequencies will be compared using the Chi-square test. Measures of central tendency (mean or median) and dispersion (percentiles, standard deviation) will be calculated for continuous variables. Normality will be assessed using the Shapiro-Wilk or Kolmogorov-Smirnov methods.

Analyses will be conducted to verify the association or correlation between the scores obtained and the outcomes under analysis (length of hospital stay and NICU stay; HPIV, mortality). Repeated assessment measures will be compared between groups using the Friedman test, and may be evaluated in relation to the outcomes using GEEs (Generalized Estimating Equations).

Multiple logistic regression will be used to identify potential predictors of NIV success or failure, calculating odds ratios with 95% confidence intervals (CI). The variables selected for multivariate analysis will be those that correspond to p-values less than 0.1 in the univariate analysis.

Data tabulation will be performed using Microsoft Excel® version 2010, and statistical analyses will be conducted using 'The Statistical Package for the Social Sciences' (SPSS®) version 20.0. Results will be presented as mean, standard deviation, absolute frequency, median, minimum, and maximum. A statistically significant value is considered when p ≤ 0.05.

DEMOGRAPHIC CHARACTERISTICS

The population of this trial consists of preterm newborns with a gestational age ≥ 28 weeks of both sexes, admitted to the NICU of the Inácia Pinto dos Santos Hospital.

CLINICAL SCORES AND PROGNOSES

Classification of gestational age at birth according to the World Health Organization (WHO):

  • Extremely premature infants, when gestational age \< 28 weeks;
  • Very premature, when gestational age > 28 and \< 32 weeks;
  • Prematuros moderados/tardios, quando IG ≥32 semanas e \< 37 semanas.

Birth weight classification according to the WHO:

  • Low weight: \< 2500g e ≥1500g;
  • Very low weight: \< 1500g;
  • Extremely low weight: \< 1000g.

Apgar score:

  • From 0 to 3 - Severe asphyxia;
  • From 4 to 6 - Moderate asphyxiation;
  • From 7 to 10 - Good vitality, good adaptation.

Silverman-Andersen Bulletin .

Interpretation of results:

  • O - There is no respiratory discomfort;
  • 1 to 3 - mild respiratory discomfort;
  • 4 to 7 - moderate respiratory discomfort;
  • 8 to 10 - severe respiratory distress.

Brazelton's adapted sleep-wake cycle assessment scale.

  • Stage 1 - Deep sleep, no movement, regular breathing;
  • Stage 2 - Light sleep, eyes closed, some body movement;
  • Stage 3 - Drowsy, eyes opening and closing;
  • Stage 4 - Awake, eyes open, minimal body movements;
  • Stage 5 - Fully awake, vigorous body movements;
  • Stage 6 - Crying.

Nasal and upper lip assessment for newborns on non-invasive ventilation.

Score:

  • 0 - No injury
  • 1-4 - Injury
  • 5-6 - Moderate injury
  • ≥ 7 - Lesão grave

Stages of nasal septum injury .

Score:

  • 0 - Normal
  • 1 - Pink/red
  • 2 - Bleeding or ulcer
  • 3 - Skin and/or cartilage rupture

classification by Papile et al. Grade I: Hemorrhage restricted to the germinal matrix Grade II: Intraventricular hemorrhage without ventricular dilation Grade III: Intraventricular hemorrhage with ventricular dilation Grade IV: Intraparenchymal Hemorrhage

WEIGHT-STATURE VARIABLES Weight, height, head circumference (InterGrowth-prematures).

LABORATORY TESTS

The following imaging exams will be collected on a form: chest x-ray, transfontanellar ultrasound, and echocardiography; and the following laboratory tests: blood gas analysis, complete blood count, white blood cell count, and cultures collected routinely or as needed for the patient, as discussed by the multidisciplinary team.

MEDICATIONS

Data on antenatal and postnatal corticosteroid use, caffeine and aminophylline, antibiotics, and analgesic-sedative medication will be collected on a form. Duration of use, dosage, and indication for use will be recorded.

MONITORING

Data collection will be done on an individual form and at the same time interval for all groups. Care and monitoring of the newborn's vital signs on non-invasive ventilation (NIV) is continuous, with supervision performed every 4 hours, which includes:

  1. Monitoring and adjusting ventilatory parameters;
  2. Evaluation and adjustments to the interface positioning ;
  3. Check the circuit for condensation causing vibrations and alterations in the airflow supplied by the AVPM and correct it ;
  4. Check for air leaks exceeding 20% and correct them;
  5. Check the humidifier temperature and refill the humidifier jug if necessary;
  6. Position the patient correctly and maintain elastic or inelastic wrapping, or the Sanovie® positioner;
  7. Monitoring related to lighting and ambient noise is ongoing ;
  8. To promote interaction between mother and newborn through skin-to- skin contact Clique ou toque aqui para inserir o texto.

Weaning and withdrawal from NIV (Non-Invasive Ventilation)

Ventilatory weaning, the process of withdrawing non-invasive ventilation (NIV), will begin when there is hemodynamic stability, absence of respiratory distress, absence of apneas and significant respiratory pauses, according to the following criteria:

  • FiO2 below 25% ;
  • PEEP ≤ 5 cmH2O ;
  • SpO2 between 92 % and 96% .
02

Conditions studied

  • Respiratory Distress Syndrome in Premature Infants
  • Non Invasive Ventilation (NIV)
  • Nasal Injury

Keywords

  • NIV interfaces
  • Preterm infants
  • respiratory distress neonatal
  • nasal injuries
  • nasal mask
  • nasal prongs
03

In context

Respiratory Distress Syndrome In Premature Infants

34 studies on the registry are indexed under Respiratory Distress Syndrome In Premature Infants; 10 are open to participants now.

This study's planned enrollment of 360 is above the median of 45 across 29 interventional studies indexed under Respiratory Distress Syndrome In Premature Infants.

Browse Respiratory Distress Syndrome In Premature Infants studies →

Lead sponsor

University of Sao Paulo General Hospital is the lead sponsor of 612 studies on the registry; 99 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Weeks to 36 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Preterm infants (PTIs) with a gestational age of ≥ 28 weeks admitted to the Neonatal ICU;
  • PTIs with mild to moderate respiratory distress (identified by the Silverman-Andersen score);
  • Participation in the study authorized by parents or legal guardians via the signing of an form.

Exclusion criteria

Exclusion criteria:

  • Patients with multiple congenital malformations;
  • Patients with intolerance to the use of NIV interfaces. Intolerance to interface use is defined as: psychomotor agitation, a ≥ 20% change in vital signs (increase or decrease) relative to the infant's baseline values, and/or a drop in peripheral oxygen saturation (SpO2) below the target range for the infant.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    Group 1 - intervention with Infant Flow LP®

    will undergo NIV via the interfaces used in the Infant Flow LP® system, according to the study protocol

    Device: Infant Flow

  • Experimental
    Group 2 - RAM® Cannula

    will receive NIV with the RAM® cannula interface, according to the study protocol

    Device: Ram Cannula

  • Experimental
    Group 3 - Dräger Babyflow® nasal mask

    will receive NIV via the Dräger Babyflow® interface, according to the study protocol

    Device: Baby Flow nasal mask

  • Experimental
    Group 4 - Conventional binasal prongs

    will receive NIV via a conventional binasal prong interface ( Ventcare® ) according to the study protocol

    Device: Conventional binasal prongs

  • Experimental
    Group 5 - Fanem® Flexible Anatomical Binaural Prongs

    Non-invasive ventilation (NIV) will be administered via a flexible anatomical binasal prong-type interface, as per the study protocol

    Device: Fanem Flexible Anatomical Binaural Prongs

Interventions

  • DeviceInfant Flow

    Infant Flow LP non-invasive ventilation interface

  • DeviceRam Cannula

    Ram Cnnula non-invasive ventilation interface

  • DeviceBaby Flow nasal mask

    Baby flow nasal mask non-invasive ventilation interface

  • DeviceConventional binasal prongs

    Conventional binasal prongs non-invasive ventilation interface

  • DeviceFanem Flexible Anatomical Binaural Prongs

    Fanem Flexible Anatomical Binaural Prongs non-invasive ventilation interface

06

What researchers measure

Primary outcomes

  1. Incidence of Non-Invasive Ventilation (NIV) Failure

    NIV failure is reported as a single composite binary outcome (Yes/No per participant) defined as the occurrence of at least one of the following standardized clinical criteria: Inspired oxygen fraction (FiO2) \> 60%; Positive end-expiratory pressure (PEEP) \> 8 cmH2O; Peak inspiratory pressure (PIP) \> 20 cmH2O or required pressure delta ≥ 12 cmH2O; Increase or lack of reduction in respiratory rate within 2 hours after NIV initiation (without fever or pain); Silverman-Andersen Score (SAS) \> 6, or recurrent apneas; SpO2/FiO2 ratio ≤ 180, or blood gas analysis with pH \< 7.22; Altered behavioral state assessed by the adapted Brazelton scale (states 5 or 6); Hemodynamic instability requiring clinical intervention; Severe cardiac arrhythmias or persistent bradycardia; Severe abdominal distension requiring NIV interruption;Worsening of underlying disease associated with deterioration of vital signs; Grade 3 nasal injury and/or upper lip facial injury score ≥ 7.

    Time frame: From enrollment (Day 1) up to NIV discontinuation or hospital discharge, whichever occurs first, assessed up to 60 days (an average of 14 days).

Secondary outcomes

  1. Compare the effectiveness of the 5 VNI interfaces

    Incidence of Non-Invasive Ventilation (NIV) Failure • Number of preterm infants who experience NIV failure, defined as the need for endotracheal intubation or escalation of ventilatory support according to protocol criteria.

    Time frame: Up to hospital discharge, an average of 60 days.

  2. Incidence and Severity of Interface-Related Skin Injuries

    Incidence of skin and mucosal injuries caused by the interfaces or fixation devices. Severity is classified into stages: Stage 1 (non-blanchable erythema), Stage 2 (superficial erosion/partial-thickness skin loss), and Stage 3 (tissue necrosis).

    Time frame: Daily during non-invasive ventilation (NIV) support, from enrollment up to NIV discontinuation (assessed up to 30 days, an average of 14 days).

  3. Preterm Infant Behavior During Ventilatory Support

    The newborn's level of alertness was assessed using an adapted version of the Brazelton Neonatal Behavioral Assessment Scale. This assessment classifies the newborn's behavioral state on a six-point ordinal scale, ranging from 1 (deep sleep) to 6 (agitated alertness). These represent categories within a single assessment, aimed at measuring the newborn's behavioral state.

    Time frame: Daily during NIV support, from enrollment up to NIV discontinuation (an average of 14 days).

  4. NIV Modes, Escalation, De-escalation, and Ventilatory Parameters

    Record of NIV modes applied, escalation/de-escalation events, and parameters including PEEP, PIP (cmH2O), Inspiratory time, Rise time (seconds), Flow (L/min), and FiO2 (%).

    Time frame: Continuously during NIV support, from baseline up to NIV discontinuation (an average of 14 days).

  5. Duration of Ventilatory Support

    Total number of days the infant requires non-invasive ventilatory support.

    Time frame: From randomization until complete NIV weaning, assessed up to hospital discharge (an average of 60 days).

  6. Length of Stay in NICU and Hospital

    Total duration of stay in the Neonatal Intensive Care Unit (NICU) and total hospital stay.

    Time frame: From date of admission/randomization through hospital discharge, assessed up to 120 days.

  7. Incidence of Peri-Intraventricular Hemorrhage (PIVH) and Periventricular Leukomalacia (PVL)

    Incidence of PIVH assessed via cranial ultrasonography according to Papile's classification: * Grade I: Hemorrhage restricted to the germinal matrix * Grade II: Intraventricular hemorrhage without ventricular dilation * Grade III: Intraventricular hemorrhage with ventricular dilation * Grade IV: Intraparenchymal hemorrhage Incidence of periventricular leukomalacia will also be recorded as present or absent.

    Time frame: From enrollment up to hospital discharge (assessed up to 120 days, an average of 60 days).

  8. Incidence of Air Leak Syndrome

    Percentage of infants developing air leak complications, including pneumothorax, pneumomediastinum, and subcutaneous emphysema, confirmed by clinical assessment and/or chest radiography.

    Time frame: Through NIV support duration, assessed up to hospital discharge (an average of 60 days).

  9. Neonatal Pain Score Measured by NIPS

    Pain level evaluated using the Neonatal Infant Pain Scale (NIPS). The scale assesses 6 parameters (Facial Expression, Cry, Breathing Patterns, Arms, Legs, and State of Arousal), each scored from 0 to 1 or 0 to 2, yielding a total score ranging from 0 to 7: * 0-2: Mild or no pain * 3-4: Mild to moderate pain * 5-7: Moderate to severe pain

    Time frame: Evaluated every 12 hours during NIV support, from baseline up to NIV discontinuation (assessed up to 30 days, an average of 14 days).

  10. All-Cause In-Hospital Mortality

    incidence of all-cause mortality among patients who participated in the study(%)

    Time frame: From enrollment through hospital discharge, assessed up to 120 days.

  11. Incidence and Severity of Interface-Related Skin and Facial Injuries

    Incidence and severity of skin and mucosal injuries caused by non-invasive ventilation (NIV) interfaces or fixation devices. Injury severity is evaluated using a dedicated 6-domain anatomical assessment tool (evaluating the tip of the nose, nasal septum, nostrils, nasal shape, nasal bridge, and upper lip). Each domain is scored from 0 (normal/no injury) to 4 (severe tissue loss/skin breakdown), yielding a cumulative total score ranging from 0 to 24. The total score is categorized as: 0 = No injury (best outcome) 1 to 4 = Mild injury 5 to 6 = Moderate injury 7 or greater = Severe injury (worst outcome)

    Time frame: Daily during non-invasive ventilation (NIV) support, from enrollment up to NIV discontinuation (assessed up to 30 days, an average of 14 days)

07

Study locations

1 of 1 sites recruiting
  • Fundação Hospitalar de Feira de Santana
    Feira de Santana, Estado de Bahia 44024366, Brazil
    Recruiting
08

References and documents

Publications

  • Keszler M. The long road to acceptance. Commentary on O. Chowdhury et al.: Randomised trial of volume-targeted ventilation versus pressure-limited ventilation in acute respiratory failure in prematurely born infants (Neonatology 2013;104:290-294). Neonatology. 2013;104(4):295-7. doi: 10.1159/000354956. Epub 2013 Oct 10. No abstract available. PubMed 24135811 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Nov 2028, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2026
First posted
Nov 18, 2026
StartActual
Sep 19, 2025
Primary completionEst.
Nov 30, 2028
CompletionEst.
Dec 30, 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944794
Responsible party
André Luis Bispo Neves (Physiotherapy Service Coordinator, Master's student, University of Sao Paulo General Hospital) — Principal investigator
First posted
Nov 18, 2026
Start date
Sep 19, 2025
Primary completion
Nov 30, 2028 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

André LB Neves
Contact
andrelbneves@usp.br
+5575992637926
Cíntia Johnston, PHD
Contact
cintia.johnston@hc.fm.usp.br
+5511982320542
Cíntia Johnston, PHD
study chair · University of Sao Paulo General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion